Wendy Tate, PhD

In my current role at Nimblify, I collaborate with institutions and other clinical research stakeholders to develop and validate meaningful and quality metrics regarding various aspects of clinical trial operations.
Pharmaceutical Sciences
Pharmaceutical Economics, Policy and Outcome
Director of Analytics
Dissertation Title: 
Evaluation of Efficiency in the Activation and Accrual of Interventional Clinical Trials as Cancer Centers
Year Enrolled: 

BS Molecular and Cellular Biology (2001), The University of Arizona
MS Applied Biosciences (2005), The University of Arizona

Research Interests: 
  • Pharmaceutical regulations and ethics
  • Research Compliance and Policy
  • Cancer
Honors and Achievements: 
1. Graduate Track Awards: Academic Excellence, 2014-15.
2. The Arizona Chapter of the Healthcare Information and Management Systems Society (AzHIMSS) Award, 2014-15.

1. Tate WR, Skrepnek, GH. Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST): Patient Reported Outcome or Mathematical Model? A Systematic Review in Cancer. Psycho-Oncology; 24(3):253-61, 2015.​
2. Skrepnek GH, Tate WR. Clinical and Economic Characteristics of Richter’s Syndrome in Chronic Lymphocytic Leukemia Inpatient Cases within the United States, 2001-2010. Leuk Lymphoma, Apr;55(4):834-840, 2014.
3. Baker AF, Koh MY, Williams R, James B, Wang H, Tate WR, Gallegos A, Von Hoff DD, Han H, Powis G. Identification of Thioredoxin-Interacting Protein-1 (TXNIP) as a HIF-1α Induced Gene in Pancreatic Cancer. Pancreas; 2008;36:2.
4. Baker AF, Landowski T, Dorr R, Tate WR, Gard JM, Tavenner BE, Dragovich T, Coon A, Powis G. The Antitumor Agent Imexon Activates Antioxidant Gene Expression: Evidence for an Oxidative Stress Response. Clinical Cancer Research, Jun 1;13(11):3388-94, 2007.
5. Baker AF, Bellamy W, Tate WR, Bair W, Heaton R, List A. Suppressor of Cytokine Signaling-3 (SOCS-3) is Over-Expressed in Erythroid Precursors of Myelodysplastic Syndrome. Leukemia, Sep;20(9):1620-1, 2006.
6. Baker AF, Dragovich T, Tate WR, Ramanathan R, Roe D, Hsu C-H, Kirkpatrick DL, Powis G. The Thioredoxin-1 Inhibitor PX-12 (1-Methylpropyl 2-Imidazolyl Disulfide) Decreases Thioredoxin-1 and VEGF Levels in Patient Plasma. The Journal of Laboratory and Clinical Medicine, Feb;147(2):83-90, 2005.
7. Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, Abraham R, Kirkpatrick L and Powis G. The Phosphoinositide-3-Kinase Inhibitor PX-866 Overcomes the Resistance of A-549 Human Non Small Cell Lung Cancer Xenografts to the EGF Receptor Inhibitor Gefitinib and a Decreased Blood Tolerance is Reversed by the PPARγ Ligand Pioglitazone. Molecular Cancer Therapeutics, Sep;4(9):1349-57, 2005.
8. Jordan BF, Runquist M, Raghunand N, Gillies RJ, Tate WR, Powis G and Baker AF. The Thioredoxin-1 Inhibitor PX-12 Decreases Vascular Permeability in Tumor Xenografts Monitored by Dynamic Contrast Enhanced MRI. Clinical Cancer Research, Jan 15;11(2 Pt1):529-36, 2005.
9. Tate WR, Skrepnek GH, "Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST): Patient Reported Outcome or Mathematical Model? A Systematic Review in Cancer." Psycho-Oncology. 2015 Mar;24(3):253-61.


Career Type: